ProCE Banner Activity

An Expert’s Guide to WCLC 2020: A Preview of the Top Abstracts

Conference Coverage
Clinical Thought
Review experts’ perspectives on the most clinically relevant emerging data in lung cancer to be presented at the virtual WCLC 2020 annual meeting, including key insights and the latest data you need to understand and integrate into your practice.

Released: January 26, 2021

Expiration: January 25, 2022

Share

Faculty

Shirish Gadgeel

Shirish Gadgeel, MD

Professor
Division of Hematology/Oncology
Department of Internal Medicine
University of Michigan
Ann Arbor, Michigan

Nicolas Girard

Nicolas Girard, MD, PhD

Professor
Chair of Medical Oncology
Head of the Thorax Institute Curie-Montsouris
Institut Curie
Universite Paris-Saclay
Paris, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Bristol Myers Squibb

Ipsen Biopharmaceuticals Inc

Janssen Pharmaceutica NV

Jazz Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Takeda Oncology

Faculty Disclosure

Primary Author

Shirish Gadgeel, MD

Professor
Division of Hematology/Oncology
Department of Internal Medicine
University of Michigan
Ann Arbor, Michigan

Shirish M. Gadgeel, MD, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Pfizer, Roche/Genentech, and Takeda; fees for non-CME/CE services from Merck Sharp & Dohme and Xcovery; and other financial or material support from AstraZeneca and Roche/Genentech.

Nicolas Girard, MD, PhD

Professor
Chair of Medical Oncology
Head of the Thorax Institute Curie-Montsouris
Institut Curie
Universite Paris-Saclay
Paris, France

Nicolas Girard, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, PharmaMar, Roche, Sanofi, and Teva, and funds for research support from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, and Roche.